伴侣动物药品市场规模、份额及成长分析（依产品类型、动物种类、给药途径、通路及地区划分）－2026-2033年产业预测

全球伴侣动物药品市场规模预计在 2024 年达到 172 亿美元，从 2025 年的 186.1 亿美元增长到 2033 年的 349.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.2%。

全球伴侣动物药品市场正经历强劲增长，这主要得益于宠物饲养率的上升以及人们日益增强的动物福利意识推动了宠物健康支出的增加。抗感染剂、疫苗、疼痛管理方案和皮肤病产品的需求激增，尤其是针对犬猫这种主要伴侣动物。兽医诊断和药物传输技术的进步，以及个人化宠物医疗的兴起，正在推动市场创新。关节炎和肥胖等慢性疾病发生率的上升，也促使人们对持续治疗方案的需求日益增长。宠物人性化的趋势，尤其是在北美和欧洲，以及兽医远端照护和线上药局的兴起，都提高了宠物获得治疗的便利性。同时，亚太和拉丁美洲地区由于经济发展和兽医基础设施的改善，也展现出巨大的成长潜力。

全球伴侣动物药品市场驱动因素

全球伴侣动物药品市场的主要驱动因素之一是宠物饲养的日益普及以及人们对动物健康和福利意识的不断提高。随着越来越多的家庭饲养宠物，对先进兽医服务的需求也不断增长，包括预防性药物、慢性病治疗和综合健康管理方案。此外，宠物饲主越来越意识到定期带宠物就诊和药物干预的重要性，从而推动了对创新药物研发和治疗方法的投资。兽医学的进步以及宠物作为家庭成员地位的日益提升，进一步强化了这一趋势。

限制全球伴侣动物药品市场的因素

全球伴侣动物药品市场的主要阻碍因素之一是动物用药品监管审查日益严格，核准流程也更加严苛。这种复杂性导致研发週期延长、生产成本上升，阻碍创新和市场准入，尤其对中小企业而言更是如此。此外，严格的合规要求限制了新产品的供应，影响了市场的整体成长潜力。而且，产品召回和安全问题会削弱消费者信心，进一步抑制该产业的需求和投资。这些监管挑战对希望扩大市场份额的相关人员构成了持续的障碍。

全球伴侣动物医药市场趋势

全球伴侣动物药品市场正呈现向高端治疗药物发展的显着趋势，这主要得益于宠物日益拟人化的趋势。宠物饲主越来越希望获得与人类同等水平的医疗保健解决方案，从而推动了针对文明病、心理健康和疼痛管理的治疗方法需求。这种转变促进了处方药、长效注射和抗焦虑药物的成长，尤其是在宠物拥有率高、动物福利意识普遍增强的都市区。随着消费者越来越将宠物视为家庭成员，市场亟需进一步的创新和产品开发，以满足这些不断变化的需求。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球伴侣动物药品市场规模（依产品及复合年增长率划分）（2026-2033 年）

• 製药
  • 抗寄生虫药物
  • 抗发炎药
  • 抗感染剂
  • 皮质类固醇
  • 镇静剂
  • 循环系统药物
  • 消化器官系统药物
• 疫苗
  • 减毒活病毒疫苗（MLV）
  • 灭活疫苗
  • 重组疫苗
• 药用饲料添加剂
  • 抗生素
  • 维他命
  • 胺基酸
  • 酵素
  • 抗氧化剂
  • 益生元和益生菌
  • 矿物
  • 碳水化合物
  • 丙二醇

全球伴侣动物药品市场规模（以动物类型划分）及复合年增长率（2026-2033 年）

• 狗
• 猫
• 马
• 其他动物物种

全球伴侣动物药品市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 注射
• 外用
• 其他给药途径

全球伴侣动物药品市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 兽医院药房
• 电子商务
• 零售药房

全球伴侣动物药品市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Zoetis Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Merck & Co., Inc.（United States）
• Elanco Animal Health Incorporated（United States）
• IDEXX Laboratories, Inc.（United States）
• Virbac SA（France）
• Ceva Sante Animale SA（France）
• Dechra Pharmaceuticals PLC（United Kingdom）
• Vetoquinol SA（France）
• Phibro Animal Health Corporation（United States）
• Bayer AG（Germany）
• Norbrook Laboratories（United Kingdom）
• Krka, dd, Novo mesto（Slovenia）
• Intas Pharmaceuticals（India）
• Hester Biosciences Ltd.（India）
• Zydus Animal Health（India）
• Abbott Laboratories（United States）
• IDT Biologika（Germany）
• Bimeda（Ireland）
• Neogen Corporation（United States）

结论与建议

Global Companion Animal Pharmaceuticals Market size was valued at USD 17.2 Billion in 2024 and is poised to grow from USD 18.61 Billion in 2025 to USD 34.97 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global companion animal pharmaceuticals market is experiencing robust growth, propelled by rising pet adoption and increased expenditure on pet health fueled by heightened awareness of animal welfare. Demand for anti-infectives, anti-parasitics, vaccines, pain management solutions, and dermatology products is surging, particularly for dogs and cats, the predominant companion species. Advancements in veterinary diagnostics and drug delivery technologies, alongside the rise of personalized medicine for pets, are driving market innovation. The growing incidence of chronic conditions, such as arthritis and obesity in companion animals, increases the need for ongoing therapeutic options. Trends relating to pet humanization, particularly in North America and Europe, along with the rise of veterinary telemedicine and e-pharmacies, enhance treatment accessibility, while Asia-Pacific and Latin America exhibit significant growth potential due to economic development and improved veterinary infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Animal Pharmaceuticals Market Segments Analysis

Global Companion Animal Pharmaceuticals Market is segmented by Product, Animal Type, Route of Administration, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Medicated feed additives. Based on Animal Type, the market is segmented into Dogs, Cats, Horses and Other animal types. Based on Route of Administration, the market is segmented into Oral, Injectable, Topical and Other routes of administration. Based on Distribution Channel, the market is segmented into Veterinary hospital pharmacies, E-commerce and Retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Companion Animal Pharmaceuticals Market

One of the key market drivers for the global companion animal pharmaceuticals market is the increasing prevalence of pet ownership and the growing awareness of animal health and welfare. As more households adopt pets, there is a rising demand for advanced veterinary care, including preventive medications, treatments for chronic diseases, and overall health management solutions. Additionally, pet owners are becoming more educated about the importance of regular veterinary visits and pharmaceutical interventions, driving investment in innovative drug development and therapeutic treatments. This trend is further supported by advancements in veterinary medicine and the humanization of pets, emphasizing their role as family members.

Restraints in the Global Companion Animal Pharmaceuticals Market

One significant restraint in the Global Companion Animal Pharmaceuticals Market is the increasing regulatory scrutiny and stringent approval processes for veterinary drugs. This complexity can lead to longer development timelines and higher costs for manufacturers, discouraging innovation and market entry, particularly for smaller firms. Additionally, the rigorous compliance requirements can limit the availability of new products, impacting the overall growth potential of the market. Furthermore, issues related to product recalls and safety concerns can undermine consumer trust, further dampening demand and investment in this sector. These regulatory challenges present ongoing obstacles for stakeholders aiming to expand their presence in the market.

Market Trends of the Global Companion Animal Pharmaceuticals Market

The Global Companion Animal Pharmaceuticals market is experiencing a notable trend towards premium therapeutics, fueled by the increasing humanization of pets. Pet owners are seeking healthcare solutions that mirror those available for humans, leading to a rising demand for therapies addressing lifestyle diseases, mental wellness, and pain management. This shift is propelling the growth of prescription therapeutics, long-acting injectables, and anti-anxiety treatments, particularly in urban areas where pet ownership and sentiment towards animal welfare are heightened. As consumers increasingly view their pets as family members, the market is poised for further innovations and product developments tailored to meet these evolving needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Companion Animal Pharmaceuticals Market Size by Product & CAGR (2026-2033)

• Market Overview
• Drugs
  • Antiparasitic
  • Anti-inflammatory
  • Anti-infectives
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
• Vaccines
  • Modified live vaccines (MLV)
  • Killed inactivated vaccines
  • Recombinant vaccines
• Medicated feed additives
  • Antibiotics
  • Vitamins
  • Amino acids
  • Enzymes
  • Antioxidants
  • Prebiotics and probiotics
  • Minerals
  • Carbohydrates
  • Propanediol

Global Companion Animal Pharmaceuticals Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Dogs
• Cats
• Horses
• Other animal types

Global Companion Animal Pharmaceuticals Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical
• Other routes of administration

Global Companion Animal Pharmaceuticals Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies

Global Companion Animal Pharmaceuticals Market Size & CAGR (2026-2033)

• North America (Product, Animal Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Product, Animal Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Animal Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Animal Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Animal Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d., Novo mesto (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Animal Health (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations